Fonds InvesteringsRijpe Starters (FIRST) finances pioneering scientists that push the boundaries of science and create groundbreaking ideas to transform the lives of patients with chronic diseases. As pre-seed stage investment fund, FIRST aims to support the start of the path from a breakthrough scientific discovery towards a meaningful treatment solution for patients.

At FIRST, we focus on the emerging fields of regenerative medicine and cardiovascular diseases. We support the leading scientists in these fields to turn their breakthrough discoveries into sustainable, innovative companies that can develop the products needed to improve patient’s lives. We harness their excellent science, foster the development into a product vision, and leverage our extensive network to attract follow-on investments.

FIRST is founded by the Dutch CardioVascular Alliance (DCVA) and Regenerative Medicine Crossing Borders (RegMed XB) with support of the Dutch Ministry of Economic Affairs and Climate Policy (under the TTT-regeling). The DCVA and RegMed XB are public-private partnerships that bring together the best scientists in The Netherlands to discover new regenerative and cardiovascular medicine and solutions to prevent and cure chronic diseases.

The FIRST fund is managed by Rianne Ellenbroek. BGV supports Rianne and the FIRST fund as registered fund manager, making available its network, expertise, and facilities. We work closely with the Valorisation teams of the DCVA and RegMed XB. For more information please reach out to

Portfolio FIRST